TheStreet restated their buy rating on shares of Merck & Co (NYSE:MRK) in a report issued on Wednesday, Stock Ratings News reports.
“Merck (MRK) has been reiterated by TheStreet Ratings as a buy with a ratings score of A. Among the primary strengths of the company is its solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income.,” the firm’s analyst commented.
Shares of Merck & Co (NYSE:MRK) traded up 0.46% during mid-day trading on Wednesday, hitting $55.2956. The stock had a trading volume of 1,094,933 shares. Merck & Co has a 52-week low of $42.10 and a 52-week high of $55.93. The stock’s 50-day moving average is $52.62 and its 200-day moving average is $49.02. The company has a market cap of $161.6 billion and a P/E ratio of 37.44.
Merck & Co (NYSE:MRK) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $0.88 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.88. The company had revenue of $11.30 billion for the quarter, compared to the consensus estimate of $11.39 billion. During the same quarter in the previous year, the company posted $0.83 earnings per share. The company’s revenue for the quarter was down 3.6% on a year-over-year basis. On average, analysts predict that Merck & Co will post $3.45 earnings per share for the current fiscal year.
In other Merck & Co news, EVP Clark Golestani unloaded 5,990 shares of Merck & Co stock on the open market in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $55.47, for a total value of $332,265.30. Following the completion of the sale, the executive vice president now directly owns 6,046 shares in the company, valued at approximately $335,372. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Several other analysts have also recently commented on the stock. Analysts at Zacks reiterated a neutral rating on shares of Merck & Co in a research note on Thursday, February 6th. They now have a $56.00 price target on the stock. Separately, analysts at JPMorgan Chase & Co. raised their price target on shares of Merck & Co from $55.00 to $60.00 in a research note on Thursday, February 6th. Finally, analysts at Argus raised their price target on shares of Merck & Co from $54.00 to $62.00 in a research note on Wednesday, February 5th. They now have a buy rating on the stock. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and nine have given a buy rating to the stock. Merck & Co currently has an average rating of Buy and an average target price of $55.56.
Merck & Co, Inc (NYSE:MRK) is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.